Malaria Clinical Trial
Official title:
VRC 312: A Phase 1, Open-Label, Dose-Escalation Clinical Trial With Experimental Challenge to Evaluate Intravenous Administration of the PfSPZ Vaccine in Malaria-Naive Adults
Background:
- Malaria parasites are carried by mosquitoes, which spread the infection by biting
people. Currently, there is no effective malaria vaccine. However, studies show that
volunteers bitten many times by mosquitoes that carry weakened malaria parasites could
fight off getting sick with malaria when later exposed to normal malaria parasites.
Malaria parasites are weakened by exposing them to radiation when they are in the stage
of development called sporozoites . Only the mosquitoes are irradiated and study
volunteers are not exposed to radiation. The radiation stops the parasites from being
able to cause disease but still promote protection. For many years, it was not possible
to give these sporozoites to people as a vaccine since they could not be adequately
purified from the mosquito. Scientists have recently figured out how to produce and
isolate the weakened sporozoites so that they can be given in an injected vaccine. This
vaccine is known as the "PfSPZ vaccine".
- A malaria challenge will be used to test whether the vaccine will prevent infection. In
a malaria challenge, mosquitoes that have the malaria parasite will be allowed to bite a
participant's arm. In the event that the vaccine does not work, the malaria parasite
used for the challenge can be treated completely with common anti-malaria medications.
Participants will be treated immediately if they develop malaria symptoms.
Objectives:
- To test the safety and effectiveness of the PfSPZ vaccine.
Eligibility:
- Healthy volunteers between 18 to 45 years of age.
Design:
- Participants will be screened with a physical exam, medical history, and blood tests.
There will be five different groups of study participants, all of whom will be monitored
with frequent blood tests.
- Group 1 will have two vaccines with the lowest amount of the vaccine given 4 weeks
apart, with regular clinic visits up to 24 weeks after the second vaccine. This group
will not have a malaria challenge.
- Group 2 will have four or six vaccines given 4 weeks apart at a higher dose than group
1. A malaria challenge will be given about 3 weeks after the last vaccine. Follow-up
visits will continue through 24 weeks after the last vaccine.
- Group 3 will have four or six vaccines given 4 weeks apart at a higher dose than group
2. A malaria challenge will be given about 3 weeks after the last vaccination, as for
Group 2. Follow-up visits will continue through 24 weeks after last vaccine.
- Group 4 will have four or six vaccines given 4 weeks apart at a higher dose than group
3. A malaria challenge will be given about 3 weeks after the last vaccination. Follow up
visits will continue through 24 weeks after last vaccine.
- Group 5 will serve as a control group and will not receive the vaccine, but will have
the malaria challenge. Follow-up visits will continue through 8 weeks after the
challenge.
All participants from any group who receive a malaria challenge will be treated promptly for
malaria when it develops.
Study Design: VRC 312 is the second study of the PfSPZ Vaccine and the first study to
evaluate intravenous (IV) administration of this vaccine. The study is designed as an
openlabel evaluation of the safety, tolerability, immunogenicity and protective efficacy of
the vaccine at successively higher dosages (2000; 7500; 30,000 and 135,000 SPZ per injection)
administered by the IV route. The 3 higher dosages will be evaluated for protection against a
malaria challenge after 4 to 6 vaccinations. Control subjects are included in the malaria
challenge. The primary objectives of the study are related to the safety and tolerability of
the vaccine at the 4 dosage levels when administered IV; the secondary objectives are related
to PfSPZ vaccine-mediated protection against Plasmodium falciparum (Pf) challenge at the 3
higher dosage levels; and the exploratory objectives are related to the immunogenicity of the
PfSPZ Vaccine and defining an immune correlate of protection.
Product Description: The investigational PfSPZ Vaccine is manufactured by Sanaria, Inc
(Rockville, MD) under current Good Manufacturing Practices (cGMP). The vaccine consists of a
suspension of purified, metabolically-active, radiation-attenuated cryopreserved Pf
sporozoites formulated in cryoprotectant and dispensed in a 0.5 mL screw-cap vial containing
a 20 mcL aliquot at a concentration of 150,000 sporozoites (+/-50,000 sporozoites) per 20
mcL. The vaccine is stored in the vapor-phase of liquid nitrogen (LNVP) at -140 to -196
degrees C. The PfSPZ Vaccine is delivered by Sanaria, Inc. to the clinical investigators and
diluted in phosphate buffered saline (PBS) with 1% human serum albumin (HSA) to achieve the
correct dosage.
Subjects: Healthy subjects, 18-45 years old, who are malaria-naive. The fewest number of
subjects needed to complete the study as originally designed was 51; however, with inclusion
of study provisions for back-up challenge subjects enrollment of additional vaccinees and
options for rechallenge, as added by protocol amendments, the amended accrual allowance is 68
subjects.
Study Plan: Subjects will be enrolled in a step-wise, dose-escalation manner with stringent
stopping rules designed for subject safety. The first 12 subjects will be allocated as the
pilot subjects that comprise Groups 1, 2a, 3a, 4a; each of which includes 3 pilot subjects.
For the pilot subjects, the 1st vaccination (V1) and 2nd vaccination (V2) will be
administered no faster than one per pilot subject every 2 hours.
Before administration of the first dose to the subsequent pilot Group (dose escalation), at
least 5 weeks of cumulative safety data for the pilot subjects in a dosage group (i.e., 1
week past 2nd vaccination) must be submitted to the Safety Monitoring Committee (SMC) and the
FDA, and protocol-specified approval received for the dose escalation.
Subjects in vaccine Groups 2, 3, 4 and the Group 5 controls will be challenged by exposure to
Anopheles stephensi mosquitoes infected with Pf sporozoites in a controlled setting, followed
by testing for parasitemia at specified intervals through up to 28 days post-challenge. To
facilitate intensive daily close monitoring of clinical status and blood smears, 11 overnight
stays are required from days 7-18 post-challenge. Subjects who develop blood stage P.
falciparum infection will be treated as soon as a case is identified by the protocol
criteria. Following treatment, a subject will be considered cured when 2 consecutive daily
blood smears are negative. After establishing cure, blood smear checks may end and the
subject may discontinue overnight stays.
Challenges occur at specified timepoints in which each challenge includes vaccine recipients
and control subjects. Rechallenge options to assess for durability of protective responses
and further evaluation of immune correlates of protection are included in the protocol.
Study Duration: The study will take approximately 18 months to complete. The period of
follow-up for each vaccinated subject is through at least 24 weeks after the last
vaccination. The total duration on study will vary depending upon the schedule assignment and
whether or not the subject participates in a rechallenge. The Group 5 (challenge only)
subjects and rechallenged subjects will be followed through 8 weeks after last challenge.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |